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The management of IIIA NSCLC challenges the surgeon and the mul-
tidisciplinary team given the heterogeneity of the local disease and the 
variable incidence of regional and systemic metastasis. Invasive staging 
with pathology examination of lymph node or other tissues further 
describes the clinical extent of the disease to reﬁne treatment decisions. 
Patients with involved N2 nodes should be preferentially considered for 
entry into a prospective clinical trial, or therapy with local and systemic 
treatment(s). 
Induction therapy has been undertaken to improve survival in patients 
with clinical stage IIIA (N2) disease. Recent multi-institutional studies 
[1] have suggested a beneﬁt from induction chemotherapy. Adjuvant 
therapy has shown survival beneﬁt in various prospective randomized 
clinical trials and meta-analyses. [2, 3] 
The North American Intergroup 0139 phase III study of concurrent 
chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by 
surgical resection (S) for stage IIIA (pN2) NSCLC was designed to 
evaluate the role of resection after chemotherapy and radiation therapy. 
Pneumonectomy accounted for 14/15 postoperative deaths and may 
have compromised overall survival. The study showed that 1) progres-
sion free survival was better with resection after chemoradiotherapy, 2) 
a non-signiﬁcant survival advantage was shown with CT/RT+S; 3) pN0 
status was associated with prolonged survival, and 4) although S may 
be considered in ﬁt patients, the results with pneumonectomy are no 
different than with CT/RT alone.[4] 
The down-staging identiﬁed with induction therapy is important in 
identifying patients with improved chances for survival. Patient with 
persistent N2 disease after induction therapy have poorer survival and 
should not typically be considered as operative candidates. SWOG 
8805 (phase II) evaluated induction chemoradiotherapy followed by 
resection for patients with cStage IIIA and cStage IIIB. This strategy 
provided a pathological complete response in 22%; overall survival 
(3-years) was 27%. Patients with no residual mediastinal lymph node 
metastasis had a median survival of 30 months compared to 10 months 
with residual disease (p=0.0005). [5] Another study identiﬁed a com-
plete response rate of 28% following induction chemoradiotherapy. 5 
year survival was 35.8% compared to 9% with residual nodal disease 
(p=0.023).[6] Alternatives to the initial mediastinal staging include 
esophageal ultrasound (EUS) and transbronchial ultrasound (TBUS) 
Resection should be avoided after induction therapy in patients who 
have biopsy-proven residual tumor in the mediastinal nodes. The ben-
eﬁt of resection over and above that achieved with combined chemo-
therapy and radiation therapy is small and may carry signiﬁcant opera-
tive and perioperative risk. If only a lobectomy would be performed, 5 
year survival may reach 40% following induction CT/RT. 
Selection of optimal treatment for patient with NSCLC requires excel-
lent pretreatment staging and clinical evaluation with discussion of 
all therapeutic possibilities by the integrated multidisciplinary care 
team: thoracic surgeon, pulmonologist, radiation oncologist, medical 
oncologist, and allied specialties. The clinician balances the risks from 
local and systemic therapies of NSCLC (local disease control, pain 
relief, improved survival) and the beneﬁts of improvement in survival 
and quality of life, based upon the individual patientís characteristics, 
co-morbidities, clinical stage and perioperative evaluation. Multidisci-
plinary evaluation, consistency of clinical evaluation and therapeutic 
approach, application of proven intraoperative and perioperative tech-
niques, completeness of resection, and adequacy of mediastinal lymph 
node dissection, etc., all beneﬁt the patient by optimizing local control 
and subsequent therapeutic decisions. 
Table 1. Primary Therapy Considerations for IIIA Non-Small Cell Lung 
Carcinoma 
Note: All patients should be considered for participation into therapeu-
tic clinical trials.
• Accurate clinical staging with FDG-PET is essential for optimizing 
therapeutic recommendations.[7]
• If clinical staging conﬁrms (histologically) metastasis to N2 lymph 
nodes, chemoradiotherapy is effective.[8]. Following R0 resection, 
patients with metastasis to N2 lymph nodes should be considered for 
adjuvant chemotherapy to enhance survival.[2, 3, 9]
• The role of preoperative chemotherapy and radiation therapy for 
limited stage IIIa is unclear.[4] 
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Improving survival outcomes for patients presenting with mediastinal 
lymph nodes, Stage IIIa, N-2, motivates thoracic surgeons, medical 
oncologists and radiation oncologists alike. All desire the best treat-
ment for the most patients, but we continue to debate what current 
tactics are most likely to result model that we can readily adopt. With 
an eye to the future, most hope that a gene array or molecular identiﬁer 
will forecast which patients have tumors with genetic packages that 
are amenable to curative therapy. Alas, we are not to that point today, 
and the 30% of NSCLC patients with heterogeneous stage IIIa disease 
variously are treated with the best of intentions based on a rather 
weak foundation of clinical trials. All stage IIIa is not the same, and 
a one-size ﬁts all, bi- or tri- modal therapy is likely to be error-prone 
and unsatisfactory to us all. What is abundantly clear is that no single 
modality alone is appropriate, and the wish for surgery to be the most 
successful tactic leads us into the temptation to use it more widely than 
appropriate for the extant data. The same can be said for radiotherapy 
alone, which is clearly inferior to radiotherapy plus chemotherapy in 
patients that can tolerate chemotherapy. Unlike the stringent winnow-
ing process selecting patients for surgery, radiotherapy discriminates 
less and can more easily be applied to the entire population presenting 
with lung cancer. Poor heart and lung functions are not the same barrier 
for radiotherapy as these are for surgery. The presence of N-2 nodes 
indicates that the deranged tumor cell-line has metastatic potential 
beyond the thorax, more likely than not. Thus, it is quite clear that the 
use of chemotherapy in N-2 patients is desirable on theoretic grounds 
(they metastasize) and clinical data (survival) is better, but we must 
remember that the studies done supporting that always mandate that 
the patients have good performance status and can withstand systemic 
therapy. Cisplatin is the most universally accepted drug, but pairing it 
with another agent has not resulted in a combination that everyone is 
willing to use. Europeans have recognized this and allowed investigator 
physicians to choose what other drug to add to cisplatin. 
The landmark CALGB study initiated in 1984 established that this 
platinum-based chemotherapy added to radiotherapy was better than 
radiotherapy alone (Dillman). Over the ensuing two decades, there 
have been nationalistic tendencies to use certain chemotherapy pairs 
with cisplatin, or even carboplatinum, but no pair of drugs emerges as 
superior, and three drugs seems to increase toxicity without adding a 
survival gain. The international standard of care for stage IIIa patients 
remains chemoradiotherapy, but the drugs, the timing of the two modal-
ities (concurrent or sequential) and the penetrating question of whether 
a select subset might beneﬁt from more remains unanswered. Under-
powered phase III and highly publicized phase II studies have tried to 
establish chemotherapy for two or three cycles followed by surgery. 
Even for N-0 patients and for N-2 patients, the complete response is in 
the single digits, or if reported higher, the conﬁdence interval includes 
less than 10% (Pisters et al). Many have clamored for the newer che-
motherapy agents introduced in the 1990’s, particularly carboplatinum 
paclitaxel in the US, and while these are used, none of these have actu-
ally added substantially to the cisplatin plus a “V” drug combination.
Tri-modal therapy began with the SWOG trial 8805 (Albain et al). This 
trial’s 120 plus patients provided the data that formed the basis and the 
hypothesis for the US Intergroup 0139 trial. The backbone of both trials 
is cisplatin etoposide and concurrent radiotherapy, 45 Gy preoperative-
ly, or 61 Gy deﬁnitively in the non-surgical arm of the Intergroup trial. 
Those that had induction chemoradiotherapy had a 10 - 30% chance of 
complete pathologic response in N-2 nodes, and these patients had long 
term prospect of survival, whereas those with residual disease in nodes 
almost universally failed. Moreover, supplementary post operative 
therapy (post operative boost radiotherapy or adjuvant chemotherapy) 
only increased morbidity and did nothing to salvage these less than 
complete nodal responders.
The major trials addressing the addition of surgery remain inconclu-
sive. The largest and purest is the US Intergroup 0139, where patients 
were randomized to chemoradiotherapy to full radiotherapy dose of 
61 Gy or truncating the dose to 45 Gy when used pre-operatively, both 
concurrent with cisplatin etoposide chemotherapy (Albain 2). Despite 
a signiﬁcant beneﬁt in disease free survival, there was no signiﬁcant 
beneﬁt in overall survival. Subset analyses show a hazard to pneumo-
nectomy, particularly right sided, and a potential for beneﬁt in patients 
requiring lobectomies. The negative impact of right pneumonectomies 
on overall survival has been pinned on the tri-modal therapy implicat-
ing the radiotherapy. Martin et al ﬁrst called attention to the identical 
25% mortality from a Memorial series that used chemotherapy alone, 
and indeed many sources note increased mortality with the pneumo-
nectomy by itself without any adjuvant therapy. Andre forecast from 
over 700 French patients with N-2 NSCLC that four factors were key: 
single station, single lymph nodes, clinically obvious nodes by imaging 
did worse than incidental nodes, and using neoadjuvant chemotherapy. 
VanMeerbeck and the EORTC recently reported a trial using 2 to three 
induction cycles of chemotherapy based on a platinum plus one other 
modern drug. Nearly half of the 579 patients registered were random-
ized to resection or radiotherapy, but 47% of patients did not proceed 
after induction therapy for a variety of reasons. Despite eliminating 
some of the most unfavorable cases during the induction treatment, 
there was no difference in median or ﬁve year survival. The US Inter-
group has not been closed a minimum of 6 years, but at last report, sur-
gery achieved 27% and chemoradiotherapy 20% 5 year survival (NS). 
The EORTC trial reported 16% versus 17% 5 year survival (NS) for 
patients randomized to surgery and radiotherapy respectively. Undoubt-
edly there were differences in selection and other factors between these 
studies, but the EORTC study had the more modern chemotherapy, and 
the US Intergroup study was less successful in administering the post 
